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The recent creation of the PANDER (pancreatic-derived factor) knockout (PANKO) and acute mouse
models have revealed a biological function in the regulation of glycemic levels via promotion of
hepatic glucose production (HGP) and pancreatic b-cell insulin secretion. Therefore, we hypothe-
sized that the absence of PANDER may afford some degree of protection from high-fat diet (HFD)
induced fasting hyperglycemia. On HFD, fasting glycemic levels were signiﬁcantly lower in the
PANKO mice. Also, fasting insulin levels and the in vivo insulin response following glucose injection
were inhibited in PANKO mice. The lowered fasting glycemic levels are attributed to decreased HGP
due to the absence of PANDER. Overall, our ﬁndings further indicate PANDER impacts glycemic
levels and may represent a potential but complicated therapeutic target.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction transgenic model which overexpresses PANDER speciﬁcally in pan-Pancreatic-derived factor (PANDER, FAM3B) is a 235 amino acid
protein that is predominantly expressed and secreted from the a
and b-cells of the endocrine pancreas [1–3]. The biological function
of PANDER has been difﬁcult to elucidate but the recent creation of
the PANDER knockout (PANKO) and acute mouse models have gen-
erated robust clues into the role of PANDER in the regulation of
euglycemia [4,5]. PANKO mice displayed glucose intolerance due
to inhibited glucose-stimulated pancreatic b-cell insulin secretion
[4]. In addition, hyperinsulinemic-euglycemic clamp studies dem-
onstrated hepatic glucose production (HGP) was signiﬁcantly lower
in PANKO as compared to WT mice. Concordantly, the acute aden-
oviral mousemodel revealed overexpression of PANDER resulted in
increased fasting hyperglycemia due to increased hepatic glucone-
ogenic expression whereas fasting PANKOmice have decreased he-
patic gluconeogenic expression. In addition, treatment of isolated
murine hepatocytes with PANDER elevated gluconeogenic gene
expression and glucose output. The recently created PANDERchemical Societies. Published by E
IS, glucose-stimulated insulin
t diet; HGP, hepatic glucose
creatic-derived factor; PEPCK,
iabetes mellitus
of South Florida, Department
y, BSF 213, 4202 E. Fowler
dt).creatic b-cells has demonstrated glucose intolerance due to in-
creased HGP, but only while on a high-fat diet (HFD) [6]. Taken
together, this suggests the potential that the absence of PANDER
may protect mice on a HFD from developing gross fasting hypergly-
cemia and that PANDER action within the liver may represent a po-
tential target for limiting HFD-induced fasting hyperglycemia.
Therefore, to better understand the biological role of PANDER, we
have evaluated the newly characterized PANKO mouse while on a
HFD with regard to impact on fasting hyperglycemia and glucose
tolerance.2. Materials and methods
2.1. PANDER knockout (PANKO) mice
PANKO mice were initially developed and phenotyped at the
Children’s Hospital of Philadelphia Research Institute as previously
described [4]. Successful disruption of the PANDER gene was
conﬁrmed via PCR for all mice employed in this study as detailed
previously (Supplementary Fig. 1). Ten male PANKO and WT mice
aged 8–9 months were maintained on a 12-h light/dark cycle with
access to a HFD (45% fat by calories, 4.76 kcal/g, Research diets Inc.
#D12451) and water. Body weight, percentage weight gain, and
food consumption were measured weekly for the ﬁrst 5 weeks.
Male mice were solely utilized for this study as our previous
ﬁndings have indicted a sex-speciﬁc phenotype for the PANKOlsevier B.V. All rights reserved.
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lished by the Institutional Animal Care and Use Committee at the
Children’s Hospital of Philadelphia.
2.2. Glucose tolerance tests (GTTs)
Glucose tolerance tests were performed as previously described
[4]. In brief, mice at 5 and 10 weeks post-HFD were fasted over-
night for approximately 16 h and subsequently injected intraperi-
toneally with 2 g of glucose (Fisher Scientiﬁc) per kilogram of body
weight. Glucose levels were measured at 0, 15, 30, 60, 90, and
120 min post-injection from tail vein blood collections.
2.3. Glycemic blood measurements
Blood was typically collected from the tail vein (approximately
5 ll) at various timepoints and conditions and measured with a
glucometer (Freestyle).
2.4. Insulin tolerance tests (ITTs)
ITTs were performed as previously described [4]. In brief, mice at
5 and 10 weeks post-HFD were fasted for 4 h and then injected
intraperitoneally with 0.75 units of insulin (NovoLog) per kilogram
of body weight. Glucose levels were measured by the samemethod
and chronological timepoints as indicated for theGTT above. Results
are shown as percentage of glucose levels at the time of injection.
2.5. Quantitative RT-PCR
Livers were collected from PANKO and WT mice and immedi-
ately snap frozen in RNA later (Qiagen). RNA was then isolated
using the RNAeasy kit (Qiagen) following manufacturer’s instruc-
tions. Purity and quantity of the isolated RNA was determined by
the A260/A280. Primer and probe sets for glucose-6-phosphatase
(G6P), phosphoenolpyruvate carboxykinase (PEPCK), and 18S rRNA
were commercially received (Applied Biosystems). Relative levels
of target gene mRNA expression were normalized to b-actin, and
calculated using the 2DDCT method.
2.6. Insulin measurement
Measurement of serum insulin concentration during the GTT
was performed by tail vein blood collection in a Microvette CB
300 (Sarstedt), followed by centrifugation for serum separation
and analysis. Sera samples were stored frozen at 80 C prior to
measurement for insulin levels. Insulin content was determined
by using the Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem).
2.7. Statistical analysis
Data are typically presented as mean ± S.E.M. or for certain as-
says such as the GTT results are also analyzed by total area under
the curve (AUC). Statistical signiﬁcance between groups was deter-
mined by Student t-test (Graphpad Prism version 5.01). P value less
than 0.05 was considered signiﬁcant.Fig. 1. Body mass, weight gain, and food consumption of PANKO mice on HFD. (A)
Average body weight, (B) percentage change weight gain and, (C) food consumption
per mouse per week of PANKO andWTmice monitored weekly. Male mice aged 8–9
months were evaluated (n = 8). Values are means ± S.E. KO, knockout; WT, wild-
type.3. Results
3.1. PANKO mice exhibit similar body weight, % weight gain, and food
consumption
To determine if PANDER could impact HFD induced fasting and
postprandial hyperglycemia, PANKO and WT littermate control
male mice aged 8–9 months were placed on a 10 week HFD (45%fat). Initial testing was performed to evaluate potential regulation
of body weight and food consumption. Mice were weighed weekly
and initial mean body weights indicated PANKO mice weighed less
than WT (36.7 ± 1.6 g vs. 40.5 ± 2.1 g) but the difference was not
statistically signiﬁcant and after 5 weeks weights were almost
identical (Fig. 1A). Similar results were obtained when evaluating
% weight gain and food consumption whereby no signiﬁcant differ-
ences were observed between PANKO andWT mice (Fig. 1B and C).
These ﬁndings indicate that absence of PANDER does not inhibit or
alter HFD induced weight gain or food consumption.
3.2. Metabolic evaluation of PANKO mice
Our previous report has indicated that the PANKO mouse dis-
plays post-prandial glucose intolerance [4]. Therefore, we
measured if this result is exaggerated in the PANKO mouse during
HFD conditions. The GTT revealed that following injection, glucose
levels were higher in PANKO mice as compared to WT controls at
both 5 and 10 weeks post-HFD (Fig. 2A and C) with a signiﬁcant
difference observed when determining total AUC for all glucose
measurements during the course of the GTT (Fig. 2B and D). To
measure insulin sensitivity, ITTs were also performed at both 5
and 10 weeks post-HFD and revealed similar insulin tolerance
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served decreased insulin sensitivity observed at 10 weeks was of
similar magnitude for both PANKO and WT mice (compare Fig 2E
to F). Furthermore, we conﬁrmed that the high fat diet had the ex-
pected effects on fasting blood glucose and plasma insulin when
compared to mice fed a normal chow diet (16.7% fat by calories)
(Supplementary Fig. 2).
3.3. Fasting glycemic levels of PANKO mice
We have previously demonstrated that PANDER can increase
fasting hyperglycemic levels due to induced HGP during adenoviral
expression or recombinant protein application [5]. The liver has
also been demonstrated as a potential target for PANDER via bind-
ing studies [7]. Therefore, we examined if the absence of PANDER
could provide a protective effect in HFD induced fasting hypergly-
cemia. PANKO and WT mice were fasted for either 24 and/or 48 h
and evaluated at both 5 and 10 weeks post-HFD. Fasting glucose
levels were not signiﬁcantly different between both groups prior
to initiation of HFD (data not shown) and at 5 weeks HFD
(Fig. 3A, left grouping). However, following 10 weeks HFD, fasting
glycemic levels were higher in theWT as compared to PANKOmice
at 24 h (213.7 ± 20.1 vs. 142.8 ± 16.2 mg/dl, respectively; P < 0.05)
and 48 h (133.1 ± 6.2 vs. 107.7 ± 8.7 mg/dl, respectively; P < 0.05)
fasting (Fig. 3A, middle and right grouping). To investigate theFig. 2. Glucose intolerance in PANKO mice. (A) Intraperitoneal GTT performed by inje
indicated time points following 5 weeks of HFD. (B) AUC calculated from measured gluco
of HFD. (D) AUC of GTT at 10 weeks of HFD. (E) Intraperitoneal ITT performed by injecting
time points following 5 weeks of HFD. Results are expressed as percentage of baseline
means ± S.E. (n = 6–8). *P < 0.05 by Student t-test.potential mechanism of decreased fasting glycemia, the relative
expression of the critical gluconeogenic enzymes of G6pase and
PEPCK were examined. RT-PCR analysis of livers from mice fasted
for 24 h indicated signiﬁcantly decreased gluconeogenic expression
from the PANKO as compared to WT mice (Fig. 3B), indicating that
the absence of PANDER has a protective effect on HFD induced fast-
ing hyperglycemia via the decreased impact on hepatic gluconeo-
genic expression.
3.4. Glucose stimulated insulin levels
The observed impaired glucose intolerance in PANKO mice did
not appear to be the result of impaired insulin sensitivity and sug-
gested inhibited insulin secretion. Our previous characterization of
the PANKO mice indicated impaired glucose-stimulated insulin
secretion (GSIS) and altered calcium response in pancreatic islets
[4]. To evaluate GSIS of PANKO mice under HFD conditions, serum
insulin levels were measured at various time points following glu-
cose injection after 10 weeks of HFD. Serum insulin levels were sig-
niﬁcantly higher in the WT as compared to PANKO mice following
glucose injection at 15 (3.5 ± 0.6 vs. 1.5 ± 0.2 ng/ml, respectively;
P < 0.05) and 30 min (2.9 ± 0.5 vs. 1.5 ± 0.4 ng/ml, respectively;
P < 0.05) post-IP glucose injection (Fig. 4). Also, fasting levels of
insulin were also signiﬁcantly increased in the WT as compared
to PANKO mice (1.9 ± 0.4 vs. 0.9 ± 0.1 ng/ml, respectively;cting mice with 2 g/kg of glucose and measuring serum glucose concentration at
se levels during entire course of GTT. (C) GTT as described above following 10 weeks
mice with insulin at 0.75 units/kg and measuring glucose concentration at indicated
glucose reading. (F) ITT as described above following 10 weeks of HFD. Values are
Fig. 3. Decreased fasting glycemia and gluconeogenic expression in PANKO mice.
(A) Fasting glucose levels of PANKO and WT mice evaluated from tail vein blood
collection and measured with glucometer (Freestyle) at 5 weeks HFD/24 hour fast
(left grouping), 10 weeks HFD/24 h fast (middle grouping), and 10 weeks HFD/48 h
fast (right grouping) (n = 6–8). (B) Quantitative RT-PCR analysis of G6pase and
PEPCK gene expression in fasted livers of PANKO and WT mice (n = 3). Results are
expressed as fold above PANKO gene expression. Values are means ± S.E. *P < 0.05
by Student t-test.
Fig. 4. Inhibited glucose-stimulated insulin secretion in PANKO mice on HFD.
Insulin levels were measured during the course of the GTT in PANKO and WT mice
following 10 week HFD (n = 5). Sera samples were collected from tail vein and
insulin measurements were evaluated by ELISA (Crystal Chem). Values are
means ± S.E. *P < 0.05 by Student t-test.
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mice. Taken together, these results indicate that PANKO mice have
impaired GSIS and decreased basal insulinemia under HFD.
4. Discussion
In summary, our results are highly concordant with our previ-
ous characterization of the PANKO and acute mouse models reveal-
ing that PANDERmay have a pleiotropic role in regulating glycemia
via both the liver and the pancreatic islet. Nonetheless, this HFD
diet study is not just merely conﬁrmatory but has allowed a further
exaggeration of the phenotype and additional elucidation of the
biological function of PANDER. For example, the previous charac-
terization of PANKOmice while on a normal chow diet (Purina Diet#5008, 16.7% fat) demonstrated decreased HGP, yet fasting
glycemic levels of PANKOmice were not statistically different from
WT. Under HFD conditions, WT mice have signiﬁcantly higher gly-
cemic fasting levels at both 24 and 48 h post-fast. HGP due to glu-
coneogenesis is critical during extensive fasting (24 h) and
responsible for up to 90% of endogenous glucose production after
40 h of fasting [8]. The signiﬁcantly decreased glycemic levels of
PANKOmice after 48 hours certainly suggests that this is the result
of decreased HGP and this is further supported by the reduced glu-
coneogenic expression of G6pase and PEPCK.
Rodentmodels of type 2 diabetesmellitus (T2DM) typically have
fasting hyperglycemia with increased expression of these critical
genes [9–12]. Also, elevated fasting hyperglycemia in T2DM is a typ-
icalmetabolic abnormality and is attributed to increasedHGPdue to
decreased insulin sensitivity and hyperglucagonemia [13,14]. In
addition, high-fat feeding in animal models has been demonstrated
to signiﬁcantly contribute to insulin resistance, which is one of the
major features of metabolic syndrome [15]. Our data indicates that
the absence of PANDER provides some degree of protection against
HFD induced fasting hyperglycemia and potentially provides an
attractive therapeutic target for T2DM intervention. Interestingly,
we have recently demonstrated that circulating PANDER levels are
chronically elevated in fat, aged wild-type C57Bl/6 mice (Supple-
mentary Fig. 3) [16]. In lean (3months) and fat (8months)wild type
C57Bl/6 mice, PANDER levels were evaluated during feeding and
fasting conditions. Two primary differences in PANDER levels were
observed in thesemice: (1) PANDER levels were signiﬁcantly higher
in the fatmice compared to leanmice during feeding and fasting and
(2) serumPANDER levels in fatmice did not decreasewith fasting as
seen with lean mice. These data indicate a positive correlation
between increased bodyweight and elevated PANDER levels. There-
fore, increased PANDER levels in heavier mice may be an important
contributor to fasting hyperglycemia due to induced increasedHGP.
However, our results demonstrate that PANKOmice on HFD still
display post-prandial glucose intolerance despite decreased fasting
glycemia. It appears that in the presence of high insulin as found
following post-glucose injection, the absence of PANDER is not
additive with regard to the suppressive impact of insulin on HGP.
However, when insulin is low as found during fasting conditions,
the absence of PANDER is reﬂected by decreased HGP and this re-
sult is supported by the acute model which demonstrates that
overexpression of PANDER increases fasting hyperglycemia. In
the knockout, this impact on fasting hyperglycemia is only evident
during HFD and this may be attributed to increased insulin resis-
tance. Following the 10 week HFD, both PANKO and WT mice were
clearly becoming increasingly insulin resistant (Fig. 2E) and this
may have exaggerated the phenotypic impact on fasting glycemic
levels in the PANKO mouse.
Interestingly, the only physiological condition under which cir-
culating PANDER levels are chronically elevated is in fat, aged mice
(Supplementary Fig. 3) [16]. In lean (3 months) and fat (8 months)
wild typeC57Bl/6mice, ad libitumfedglucose levelswerenot signif-
icantly different between the two groups, but after a 24-h fast, older
mice were hyperglycemic compared to younger mice. Two primary
differences in PANDER levels were observed in thesemice: (1) PAN-
DER levelswere signiﬁcantly higher in the fatmice compared to lean
mice both during feeding and fasting and (2) serum levels in fatmice
did not decrease with fasting as with lean mice, but remained high.
These data suggest that there is a positive correlation between in-
creased body weight and elevated PANDER levels and the increased
PANDER levels in heavier mice may be an important contributor to
fasting hyperglycemia due to PANDER-induced HGP.
This study has also indicated that PANDER impacts pancreatic
b-cell function and post-prandial glucose tolerance. Initial charac-
terization of the knockout was highly confounded by the fact that
the GTT in PANKO mice on normal chow displayed higher levels of
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islet perifusion and calcium imaging studies demonstrating abnor-
mal responses of the PANKO islets to glucose stimulation. This
conﬂicting report was attributed to compensatory and protective
mechanisms that exist in vivo to preserve and maintain pancreatic
b-cell function whereas defects in GSIS are exaggerated and pro-
nounced in isolated islets as has been observed in other knockout
models [17,18]. However, as shown by this study, for the PANKO
mice under HFD conditions GSIS was inhibited and accompanied
by post-glucose injection glucose intolerance thus further support-
ing a role for PANDER in pancreatic b-cell function. Under insulin
resistant conditions as induced by the HFD, it is possible that
in vivo compensation was inadequate due to additional pressure
on the pancreatic b-cell to secrete more insulin in the scenario of
increasing resistance. Nonetheless, this result has demonstrated
that the pleiotropic role of PANDER will certainly complicate its
utility as a potential T2DM drug target in that overall PANDER inhi-
bition will result in contradictory outcomes with regard to reduc-
ing fasting glycemic levels but having impaired post-prandial
glucose tolerance.
In a physiological context, PANDER appears to serve varying
roles with regard to either interaction with the liver or pancreatic
islets, depending on the fed or fasted state. In the fed state, as dem-
onstrated by our previously published knockout mouse, PANDER
strongly impacts pancreatic b-cell function in a glucose-stimulated
manner by either regulating or facilitating insulin secretion. PAN-
KO pancreatic islets have both inhibited insulin secretion and
abnormal calcium handling. This phenotype is even further exag-
gerated in our presented high-fat model, whereas the PANKO mice
displayed glucose intolerance to a more severe extent as compared
to the WT mice with a concordant decrease in GSIS. However, in
the fasted state, as demonstrated by our acute mouse model, PAN-
DER stimulates cAMP and CREB dependent pathways that increase
gluconeogenic gene expression and overall HGP [5]. This ﬁnding is
supported by our PANKOmouse during normal diet conditions that
demonstrated decreased HGP during hyperinsulinemic-euglyce-
mic clamp studies. Our ﬁndings in this high fat diet study strongly
conﬁrm this fasting role, whereas PANKO mice display decreased
fasting glycemic levels.
Overall, our study strongly indicates that PANDER is a novel
hormone regulating glycemic levels via pancreatic b-cell insulin
secretion and hepatic gluconeogenic expression. In addition, the
absence of PANDER provides some degree of protection against
HFD induced fasting hyperglycemia and may provide a potential
therapeutic T2DM drug target but only with regard to the speciﬁc
inhibition of distal action on the liver.
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